New hope for kids with tough leukemia: drug combo targets rare gene
NCT ID NCT07437170
First seen Feb 28, 2026 · Last updated May 16, 2026 · Updated 10 times
Summary
This study tests whether adding the drug selinexor to standard chemotherapy can help children with a rare, high-risk form of acute myeloid leukemia (AML) caused by a NUP98 gene change. Ten children will receive the combination during their first two rounds of chemo. The goal is to see if more children achieve complete remission and have better long-term survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.